BSE Live
Jun 09, 16:01Prev. Close
4647.85
Open Price
4684.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jun 09, 15:59Prev. Close
4649.40
Open Price
4681.05
Bid Price (Qty.)
4666.80 (20)
Offer Price (Qty.)
0.00 (0)
Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | Mar 19 | |
Per Share Ratios | ||||||
Basic EPS (Rs.) | 157.37 | 97.85 | 131.84 | 177.23 | 76.98 | |
Diluted EPS (Rs.) | 157.03 | 97.85 | 131.46 | 176.88 | 76.85 | |
Cash EPS (Rs.) | 212.24 | 146.48 | 181.57 | 224.24 | 123.97 | |
Book Value [ExclRevalReserve]/Share (Rs.) | 1,228.94 | 1,101.94 | 1,020.66 | 914.07 | 764.10 | |
Book Value [InclRevalReserve]/Share (Rs.) | 1,228.94 | 1,101.94 | 1,020.66 | 914.07 | 764.10 | |
Dividend / Share(Rs.) | 40.00 | 30.00 | 25.00 | 25.00 | 20.00 | |
Revenue from Operations/Share (Rs.) | 1,018.16 | 865.70 | 802.23 | 713.02 | 640.09 | |
PBDIT/Share (Rs.) | 288.48 | 184.86 | 236.65 | 217.38 | 152.90 | |
PBIT/Share (Rs.) | 233.07 | 135.93 | 186.47 | 169.89 | 105.87 | |
PBT/Share (Rs.) | 232.05 | 133.64 | 183.67 | 167.02 | 102.45 | |
Net Profit/Share (Rs.) | 156.83 | 97.55 | 131.39 | 176.76 | 76.95 | |
Profitability Ratios | ||||||
PBDIT Margin (%) | 28.33 | 21.35 | 29.49 | 30.48 | 23.88 | |
PBIT Margin (%) | 22.89 | 15.70 | 23.24 | 23.82 | 16.54 | |
PBT Margin (%) | 22.79 | 15.43 | 22.89 | 23.42 | 16.00 | |
Net Profit Margin (%) | 15.40 | 11.26 | 16.37 | 24.78 | 12.02 | |
Return on Networth / Equity (%) | 12.76 | 8.85 | 12.87 | 19.33 | 10.07 | |
Return on Capital Employed (%) | 18.54 | 12.25 | 18.17 | 18.46 | 13.34 | |
Return on Assets (%) | 10.29 | 6.62 | 10.10 | 15.08 | 7.86 | |
Total Debt/Equity (X) | 0.00 | 0.12 | 0.07 | 0.07 | 0.07 | |
Asset Turnover Ratio (%) | 0.68 | 0.62 | 0.65 | 60.84 | 65.39 | |
Liquidity Ratios | ||||||
Current Ratio (X) | 3.16 | 2.23 | 2.40 | 2.42 | 2.90 | |
Quick Ratio (X) | 2.48 | 1.68 | 1.78 | 1.89 | 2.25 | |
Inventory Turnover Ratio (X) | 0.99 | 1.10 | 1.30 | 5.41 | 5.27 | |
Dividend Payout Ratio (NP) (%) | 0.00 | 25.54 | 18.96 | 13.32 | 25.99 | |
Dividend Payout Ratio (CP) (%) | 0.00 | 17.00 | 13.72 | 10.50 | 16.13 | |
Earnings Retention Ratio (%) | 0.00 | 74.46 | 81.04 | 86.68 | 74.01 | |
Cash Earnings Retention Ratio (%) | 0.00 | 83.00 | 86.28 | 89.50 | 83.87 | |
Valuation Ratios | ||||||
Enterprise Value (Cr.) | 76,399.19 | 71,782.46 | 74,673.98 | 52,829.90 | 46,829.39 | |
EV/Net Operating Revenue (X) | 4.50 | 4.98 | 5.59 | 4.46 | 4.41 | |
EV/EBITDA (X) | 15.90 | 23.34 | 18.96 | 14.62 | 18.45 | |
MarketCap/Net Operating Revenue (X) | 4.54 | 4.97 | 5.63 | 4.37 | 4.33 | |
Retention Ratios (%) | 0.00 | 74.45 | 81.03 | 86.67 | 74.00 | |
Price/BV (X) | 3.76 | 3.91 | 4.42 | 3.41 | 3.63 | |
Price/Net Operating Revenue | 4.54 | 4.97 | 5.63 | 4.37 | 4.33 | |
Earnings Yield | 0.03 | 0.02 | 0.03 | 0.06 | 0.03 |
05.06.2023
Dr Reddy’s shares gain after Phase I study of antirheumatic biosimilar ends
18.05.2023
14.05.2023
13.05.2023
Reduce Dr. Reddy's Laboratories; target of Rs 4500: Prabhudas Lilladher
10.05.2023
Dr Reddys Labs Consolidated March 2023 Net Sales at Rs 6,315.20 crore, up 15.35% Y-o-Y
10.05.2023
Dr Reddys Labs Standalone March 2023 Net Sales at Rs 4,554.00 crore, up 24.13% Y-o-Y
10.05.2023
Dr Reddy's Q4 net profit jumps to Rs 959 crore on favourable base, US launches, brand deals
25.01.2023
Dr Reddys Labs Consolidated December 2022 Net Sales at Rs 6,789.80 crore, up 27.19% Y-o-Y
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz
27.07.2022
Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%
13.07.2022
Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct